Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > News after thanksgiving
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Oct 05, 2022 3:58pm
232 Views
Post# 35007636

RE:News after thanksgiving

RE:News after thanksgiving
themagicbox wrote: IR indicated no delays for trial start and more in a NR after thanksgiving (canadian thanksgiving that is).

Don't take my word for it, go verify yourself with a email or call to IR.



Yes Sir Magic - looking forward to it !!!
Always seems to be a moving target - but - we'll get it eventually.

Lots still to be updated in 2022.  What they owe:

1.  commercial study - soon
2.  first enrolment - soon
3.  CITA closing - any day now

4.  352 update - Nov ?
5.  IBD first candidate introduction - Q4 (maybe at the same time as 352 ?)
6.  P2 Molar readout - Late Dec ?

I think that's still the list we had at the beginning of September.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities